Zhalet Baharestan, DO
Internal Medicine · Louisville, KYNPI 1962489559
Payments from drug & device makers
Across 483 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$897
- Novo Nordisk$868
- AbbVie$814
- Merck$351
- Takeda Pharmaceuticals U.S.A., Inc.$326
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,89399%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 73 | $1,356 |
| Amgen(2 entities) | 59 | $897 |
| Novo Nordisk | 43 | $868 |
| AbbVie(2 entities) | 56 | $814 |
| Merck | 24 | $351 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $326 |
| Pfizer | 14 | $325 |
| GSK | 20 | $311 |
| Lilly USA, LLC | 19 | $267 |
| Tris Pharma Inc | 15 | $248 |
| Bayer | 8 | $240 |
| Boehringer Ingelheim | 15 | $226 |
| Azurity Pharmaceuticals, Inc. | 13 | $201 |
| Endo Pharmaceuticals Inc. | 12 | $174 |
| Arbor Pharmaceuticals, Inc. | 12 | $173 |
| Exact Sciences | 9 | $167 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $155 |
| Noven Therapeutics, LLC | 8 | $140 |
| Shield Therapeutics Inc | 6 | $119 |
| Johnson & Johnson | 6 | $99 |
| Novartis | 6 | $90 |
| Kowa Pharmaceuticals America, Inc. | 5 | $77 |
| Amarin Pharma, Inc. | 4 | $58 |
| Biohaven Pharmaceuticals, Inc. | 3 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Shire North American Group Inc | 2 | $31 |
| IBSA Pharma Inc. | 2 | $28 |
| Scynexis, Inc. | 1 | $21 |
| Globus Medical | 1 | $18 |
| Abbott | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Gilead | 1 | $13 |
| Circassia Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$122
- BREZTRI$120
- Kerendia$113
- NURTEC ODT$107
- RYBELSUS$106
How this compares
$7,949 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 29 | $59,280 |
| OzempicSemaglutide | 30 | $47,001 |
| Bydureon BciseExenatide Microspheres | 25 | $31,520 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $29,962 |
| JardianceEmpagliflozin | 25 | $29,718 |
| Xigduo XrDapaglifloz Propaned/Metformin | 27 | $26,036 |
| FarxigaDapagliflozin Propanediol | 15 | $23,099 |
| Repatha SureclickEvolocumab | 16 | $19,834 |
| EliquisApixaban | 31 | $18,951 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $18,683 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $18,173 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,002 |
| TradjentaLinagliptin | 15 | $13,758 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,328 |
| Memantine Hcl ErMemantine Hcl | 24 | $5,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $868 | $106,28159 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $226 | $62,15954 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,356 | $46,60058 claims |
| GSKTrelegy Ellipta | $311 | $29,96241 claims |
| PfizerEliquis | $325 | $18,95131 claims |
| AbbVieSynthroid | $814 | $4,12044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Louisville
- Jason ChesneyLouisville$6.3M
- Robert SasserLouisville$62K
- Kelley McIntyreLouisville$48K
- Lal TanwaniLouisville$38K
- Mark WilliamsLouisville$33K
- Scott YoungLouisville$24K
- Frank SimonLouisville$22K
- Walter BruningLouisville$22K
- Brian ParadowskiLouisville$20K
- Suresh NairLouisville$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.